The hosts review increasingly alarming drug disclaimers for medications like Zepbound and Camzyos. Side effects listed include suicidal thoughts, heart failure, and death, which the hosts contrast with older, less severe pharmaceutical warnings.
12 chapters across the catalog
The hosts review increasingly alarming drug disclaimers for medications like Zepbound and Camzyos. Side effects listed include suicidal thoughts, heart failure, and death, which the hosts contrast with older, less severe pharmaceutical warnings.
The hosts acknowledge major donations from producers, including a significant contribution from Sironimus of Dogpatch. Sironimus provides travel tips for the EU and mentions a recent visit to the West Bank. Sir Scovey facilitates a series of matching donations, and other producers share personal anecdotes regarding pharmaceutical ads and the death of Charlie Kirk.
Eli Lilly Direct, Ozempic and Wegovy Price Wars
Pharmaceutical giants Eli Lilly and Novo Nordisk are engaging in a price war for obesity drugs by selling directly to consumers and bypassing insurance companies. Eli Lilly is offering Zepbound at a significant discount for patients who pay out-of-pocket. This shift highlights the "insurance scam" where manufacturers can make more profit by cutting out the middleman and lowering prices for direct buyers.
The FDA has approved the weight-loss drug Zepbound to treat obstructive sleep apnea. Medical correspondents report that the drug could effectively cure symptoms in 40% of patients. The hosts discuss the potential for Medicare and Medicaid to cover the high cost of these injectable medications, estimated at $30 billion over ten years.
Eli Lilly Zepbound Pricing, Pharmaceutical Margins
Eli Lilly announced it will sell its weight loss drug Zepbound directly to consumers for half the retail price if their insurance does not cover it. The hosts point out that the company still profits at this lower price, highlighting the extreme markups typically charged to insurance providers and Medicare.
Eli Lilly, Amazon Pharmacy Zepbound Partnership
Pharmaceutical giant Eli Lilly has partnered with Amazon Pharmacy to provide home delivery of its weight-loss drug Zepbound. The "LillyDirect" program aims to simplify access to the medication, which the hosts view as a sign of the increasingly commercialized and automated medical system.
Pharmaceutical giants Novo Nordisk and Eli Lilly are seeing record stock highs as they transition from injectable weight loss drugs to oral pill forms. Early trials of Novo Nordisk's pill, amicrotin, showed users lost 13% of their weight over 12 weeks. The industry is pivoting toward pills to lower costs and increase accessibility, with Medicare and Medicaid expected to eventually cover these treatments.
Eli Lilly has launched "Lilly Direct," a website allowing consumers to obtain prescriptions for the weight loss drug Zepbound via telehealth. In response, Novo Nordisk and other health advocates have warned about the dangers of buying "counterfeit" or "black market" versions of Ozempic online. Sharon Osbourne is cited as an example of the extreme weight loss results associated with these medications.
Weight Watchers Pivot to Obesity Care Management
Weight Watchers CEO Seema Sistani apologizes for the company's past focus on willpower, now framing obesity as a "chronic medical condition" requiring pharmaceutical intervention. The hosts analyze this as a shift toward "obesity care management" following Weight Watchers' acquisition of a telehealth service to prescribe drugs like Mounjaro.
Pharmaceutical companies are using complex rebate structures to force insurance companies to cover weight-loss drugs. By rebranding diabetes medications like Mounjaro as Zepbound for weight loss, manufacturers can leverage portfolio requirements. If an insurer wants the rebate for the diabetes version, they are often pressured to also cover the more expensive weight-loss version, turning the obesity epidemic into a high-stakes financial game.
Weight Loss Drug Marketing, Manjaro Success Stories
The FDA recently approved Zepbound, a new version of the diabetes drug Mounjaro, specifically for weight loss. Media reports have featured success stories, such as a 30-year-old woman who lost 125 pounds on the medication. While the drugs show promise for reducing inflammation and heart disease risk, experts warn they are not intended for casual weight loss and carry unknown long-term risks, especially given their high monthly cost of $1,300.
Eli Lilly Zepbound, Obesity Opportunity and Pharma Marketing
The FDA approved Eli Lilly’s drug Zepbound for chronic weight management, which is a rebranded version of the diabetes drug Mounjaro. Financial analysts describe the "obesity opportunity" as potentially the largest pharmaceutical market in history, with marketing budgets expected to reach record highs.
